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Reducing Stroke Risk in Atrial
Fibrillation: Adherence to Guidelines
Has Improved, but Patient Persistence
with Anticoagulant Therapy Remains
Suboptimal

Review Article
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ABSTRACT

Atrial fibrillation (AF) is a significant risk factor for avoidable stroke. Among high-risk
patients with AF, stroke risk can be mitigated using oral anticoagulants (OACs), however
reduction is largely contingent on physician prescription and patient persistence with OAC
therapy. Over the past decade significant advances have occurred, with revisions to clinical
practice guidelines relating to management of stroke risk in AF in several countries, and
the introduction of non-vitamin K antagonist OACs (NOACs). This paper summarises
the evolving body of research examining guideline-based clinician prescription over
the past decade, and patient-level factors associated with OAC persistence. The review
shows clinicians' management over the past decade has increasingly reflected guideline
recommendations, with an increasing proportion of high-risk patients receiving OACs,
driven by an upswing in NOACs. However, a treatment gap remains, as 25–35% of highrisk patients still do not receive OAC treatment, with great variation between countries.
Reduction in stroke risk directly relates to level of OAC prescription and therapy persistence.
Persistence and adherence to OAC thromboprophylaxis remains an ongoing issue, with
2-year persistence as low as 50%, again with wide variation between countries and practice
settings. Multiple patient-level factors contribute to poor persistence, in addition to concerns
about bleeding. Considered review of individual patient's factors and circumstances will
assist clinicians to implement appropriate strategies to address poor persistence. This review
highlights the interplay of both clinician's awareness of guideline recommendations and
understanding of individual patient-level factors which impact adherence and persistence,
which are required to reduce the incidence of preventable stroke attributable to AF.
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INTRODUCTION
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a growing health problem
worldwide given the ageing of populations.1) AF increases the risk of stroke 5-fold, and is
associated with increased risk of heart failure (HF), dementia, and all-cause mortality.2-5) The
actual prevalence of AF is likely underestimated, as a large proportion of patients remain
asymptomatic (‘silent AF’) and therefore undetected, so the first manifestations of AF may be
a debilitating stroke or death.6) Once AF is detected, the risk of cardioembolic stroke can be
effectively reduced by 64% with the commencement of oral anticoagulants (OACs), and allcause mortality is reduced by 26%.7) However, this reduction in risk is largely contingent on the
physician appropriately prescribing an OAC, and the patient persisting with this therapy.

n
o

i
is

A number of OACs, comprising of vitamin K antagonists (VKAs) such as warfarin and
non-VKA OACs (NOACs) are used to reduce stroke risk among patients with AF.8) The use
of warfarin or NOACs in high-risk patients has been shown to reduce stroke risk by up to
60–65%.9) Warfarin has traditionally been the medication of choice for managing highrisk patients with AF, until the advent and release of NOACs over the past decade, which
have been shown to be as effective as warfarin, but are associated with a lower risk of major
bleeding, particularly intracranial haemorrhage.10) Aspirin, which is sometimes used as a sole
agent, or in combination with clopidogrel, has also been used by practitioners in the past
and still continues to be used. However there is only weak evidence showing that antiplatelet
agents (APAs) prevent stroke,9) and even when used in combination (e.g. aspirin and
clopidogrel) have only been shown to have only half the efficacy of warfarin, with a similar
incidence of major bleeding episodes.11) Indeed, misperceptions about both the efficacy and
safety of aspirin in AF have probably been a major reason for perpetuation of OAC underutilization.12) Currently, the Korean,13) European,14) USA,15) and American College of Chest
Physician guidelines,16)and Australia and New Zealand9) guidelines for the management of
stroke risk in AF discourage the use of APAs altogether for stroke risk reduction in AF.
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NOACs are emerging as the preferred OACs for patients with AF at high-risk of stroke,
and this has also been reflected in recent revisions of guidelines in Korea,13) Europe,14) the
USA,15) and Australia and New Zealand9) which recommend NOACs as first-line medications.
Efficacy, safety, ease of use without the need for regular blood monitoring have led to
a gradual increase in NOAC use and a decline in warfarin or other VKA drug use for
thromboprophylaxis for AF. However, some advantages of warfarin are that adherence to
treatment can be easily monitored, it has a relatively long half-life, and a fast and effective
mechanism of reversal is readily available.17) NOACs, on the other hand, are considerably
more expensive than warfarin but have nevertheless been shown to be more cost-effective
in the longer term.18) Unfortunately, there is a paucity of readily available measures of
anticoagulation that can monitor patient adherence with NOACs, and reversal agents are less
readily accessible in the event of a major bleed,17) though that situation is changing.

Stroke risk reduction guidelines for patients with atrial fibrillation
The appropriate identification and management of stroke risk in patients with AF is vital
for reducing the incidence of avoidable stroke. New AF management guidelines have been
https://e-kcj.org
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developed and reviewed in recent years in Korea, the USA, Europe and Australia and New
Zealand.9)13-15) Revisions of these guidelines in many countries have adopted the CHA2DS2VASc/CHA2DS2-VA stroke risk assessment tool, superseding the CHADS2 score, for stratifying
stroke risk due to a marginally improved stroke prediction risk, particularly in ascertaining
those at low risk who do not require OAC.19) Patients score one point for: cardiac failure,
hypertension, diabetes, vascular disease, age 65–74 years and female sex (the latter variable
excluded from CHA2DS2-VA sexless score), and an additional point for age to give 2 points
for age ≥75 years, and 2 points for previous stroke/transient ischemic attack (TIA). The
recommendations are to commence an OAC for patients at high-risk (CHA2DS2-VASc≥2 in
a male or ≥3 in a female=CHA2DS2-VA≥2), and consideration given to OAC for those with
CHA2DS2-VA of one point, with oral anticoagulation therapy not recommended for those
with a CHA2DS2-VA of zero.9)13) While these scores are easy to calculate at the bedside, the C
statistic is only modest,16) and more complex scores including biomarkers offer a marginal
increase which makes them less practical for widespread use.

n
o

Perceived bleeding risk is one factor, especially among Asian subjects, that contributes
to sub-optimal prescribing of OACs among patients with a high risk of stroke.20) Not
surprisingly, physicians are sensitized by a major bleed in one of their patients, but do not
see the strokes they prevent. Bleeding risk can be estimated by a number of clinical scoring
systems (e.g. HAS-BLED, ATRIA), however these algorithms have been shown to be only
modest predictors of major bleeds.9) Due to similar factors predicting both stroke and
bleeding risk, patients with higher CHA2DS2-VASc/CHA2DS2-VA scores are also at higher
risk of bleeding. Current guidelines outline that the clinical benefit of stroke prevention
nearly always outweighs bleeding risk, so bleeding risk scores should not be used to
avoid anticoagulation in high-risk patients, but reversible bleeding risk factors which are
incorporated in bleeding scores, should be identified and corrected, where possible.9)
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The decision of whether to anticoagulate, and which anticoagulant to use, is made by the
treating clinician after consultation with the patient. In this rapidly evolving area of changes
to guidelines and therapies available, little is known about how prescribing practices have
reflected these changes over the past decade.

v
o

Secular trends in overall oral anticoagulant use in atrial fibrillation over the
past decade

r
P

Studies conducted in several countries over the past decade have consistently found an
increase in the proportion of patients with AF appropriately prescribed OACs. The trend of
increased use of OACs is evident from both large-scale time series analyses of patients with
AF, as well as studies using prescription databases (Figure 1 and Table 1). 17)19)21-41)
Approximately 10 years ago baseline rates of OAC use among intermediate-to-high risk
patients ranged from 45–80% in the UK21)23) and USA,31)33)34) and were substantially lower in
some Asian countries,37-39) ranging from 8–35%. In the UK,19)21) Europe24)26) and Asia,38)39) the
proportion of patients with AF who were treated with an OAC increased by more than 50%
over the decade from 2005–2015. This trend was seen for all stroke risk categories combined,
as well as among intermediate-to-high risk patients. In the US the increase was marginally
less than observed in other regions, but may have reflected the shorter time periods covered
by these studies and/or the higher baseline rate of OAC use31)33)34). After 2015, rates of OAC
prescription among intermediate-to-high risk patients increased to around 60–75% in the
UK, Western Europe and USA21)23)33) and between 50–55% in Asian countries.37-39)
https://e-kcj.org
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Figure 1. Secular trends in oral anticoagulant prescription.
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Although these findings shed a positive light on increased use of OACs to mitigate stroke risk
in AF, they also show that increased OAC use was not uniform within and between countries,
and that OAC use overall remained sub-optimal. Among the studies reviewed, only 50–70%
of patients with CHA2DS2-VASc ≥2 were treated with OACs in the more recent years of the
studies,21)34)35)38)39) leaving 30–50% of high-risk patients vulnerable to thromboembolic stroke.
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Secular trends in the use of vitamin K antagonists for stroke risk reduction in
atrial fibrillation

A number of studies have examined VKA prescription (predominantly warfarin) over the past
decade, and have found marked shifts in practice, with sharp declines in the prescription of
VKAs in most countries between 2010 and 2015. Prior to the introduction of NOACs, studies
that examined trends in VKAs suggest that VKA use was increasing steadily.27)31)39) These
studies show that prior to the introduction of NOACs VKAs were the preferred medication
and were used in 50–70% of intermediate-to-high risk patients prescribed an OAC, however
this reduced to 30–40% after the introduction of NOACs.33)34)38) These reductions in VKA
use in the last half of the previous decade have been observed in the UK,19)22) Western
Europe,24)26)28) USA,32-34) and Korea38) (Table 1).
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Secular trends in the use of antiplatelet agents as monotherapy for stroke
risk reduction in atrial fibrillation
A number of studies have documented a decline over the past decade in the use of APAs as
monotherapy for the prevention of thromboembolism among intermediate and high-risk
patients (Table 1). At the beginning of the past decade between 30–40% of patients with
CHA2DS2-VASc ≥2 in the UK,19)21)23) Western Europe24), and Korea38) were treated with APA as a
monotherapy (predominantly aspirin). Overall prevalence of APA monotherapy among highrisk groups declined to around 30% in these countries toward the end of the decade. The
only study that was an exception to this trend was a study in China, which showed a sharp
increase in aspirin monotherapy increasing from 4–46% among patients with CHA2DS2-VASc
≥2 between 2001 and 2012.39) Although there has been a notable decrease in the use of APAs
https://e-kcj.org
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Table 1. Secular trends in prescriptions for atrial fibrillation
Author (years)
United Kingdom
Apenteng et al.
(2018)19)
Cowan et al.
(2018)21)
Protty and Hayes
(2017)22)

Robson et al.
(2014)23)
Western Europe
Maura et al.
(2019)24)

Country;
study period

Source

UK;
2011–2016

GARFIELD-AF
registry

UK;
2006–2016
UK (Wales);
2009–2015

English national
databases
Welsh analytical
prescribing unit

UK (London);
2011–2013
French national
health insurance
database
Denmark; Danish nationwide
2001–2012
registries
Denmark;
Danish national
2005–2015
registries

Germany; Wissenschaftliche
2005–2014 Institut der AOK;
and national
hospitalisation
database
Urbaniak et al.
Norway;
Norwegian
(2017)28)
2012–2015
prescription
database
Sindet-Pedersen et al. Denmark;
Danish national
(2018)29)
2011–2016
prescription
registry
Haastrup et al.
Denmark;
Danish national
(2018)30)
2008–2016
prescription
registry
USA and Canada
Pilote et al.
Canada;
Hospital
(2013)31)
1998–2006 administrative
database
Weitz et al.
Canada;
Canadian
(2015)32)
2008–2014
prescription
database

r
P

3,482

Prescription initiated
at AF diagnosis
(all CHA2DS2-VASc scores)
Prescription proportion
(CHA2DS2-VASc≥2)
OAC prescriptions
(items) per 1,000
prescribing units

12,231

57,995
2,946

126,691

OAC prescription initiated
at diagnosis
(all CHA2DS2-VASc scores)
Proportion on OAC
(all CHA2DS2-VASc scores)
OAC prescription initiated
at AF diagnosis
(all CHA2DS2-VASc scores)

Annual drug treatment
rates per 100,000
persons hospitalised;
using defined daily
doses of OAC
Proportion prescribed
OAC (all CHA2DS2-VASc
scores)
NOAC prescription
initiated at diagnosis
(all CHA2DS2-VASc scores)
No. of patients prescribed
NOAC per 1,000 individuals
in the Danish population

r
P

Marzec et al.
(2017)33)
Thompson et al.
(2017)34)
Lubitz et al.
(2018)35)

USA;
2008–2014
USA;
2008–2014
USA;
2008–2014

NCDR PINNACLE
registry
NCDR PINNACLE
registry
NCDR PINNACLE
registry

655,000

Steinberg et al.
(2017)17)

USA;
2013–2016

ORBIT-AF registry

4,670

Zhu et al.
(2018)36)

USA;
2010–2017

Health insurance
database

112,187

691,906
674,841

NOAC

↑ 54.7–73.9%

↑ 2–47%

OAC prescription in newly
diagnosed AF
(all CHA2DS2 scores)
Total OAC scripts
(all indications)
Proportion on OAC
(CHA2DS2-VASc≥1)
Proportion on OAC
(CHA2DS2-VASc≥2)
OAC among patients
(CHA2DS2-VASc≥2)

NOAC prescription in newly
diagnosed AF
(all CHA2DS2-VASc scores)
NOAC prescription in
newly diagnosed AF
(CHA2DS2VASc≥2)

VKA

↑ 40.48–
65.26%

APA
monotherapy

↓ 53.3–30.6% ↓ 36.4–10.5%

↑ 48.0–78.6% ↑ 1–33% (2011–2016)

↓ 42.9–16.1%

Proportion of OAC Proportion of
defined daily doses: OAC defined
rivaroxaban: ↑ 17% daily doses: ↓
100–68%
Apixaban: ↑ to 9%
Dabigatran: ↑ to 3%

↑ 52.6–59.8%

↓ 37.1–30.3%

↑ 56.7–65.8% 0–66.3% (2015–2016)

↓ 57–41%

↓ 37.1–30.3%

↑ 32.5–53.9%
2005: 46.3%
2009: 38.1%
2015: 66.5%

↑ 0–49% (2011–2015)

↓ 50–18%

l
a

↑ 0–0.6% (of all
↑ 0.9–12.3%
people hospitalised) (of all people
hospitalised)

n
o
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is
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338,479

All OACs
combined

l
a

Prescription proportion
(CHA2DS2-VASc≥1)

n
o

2,913,769

i
is
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Gülker et al.
(2018)27)

Secular trend over study period

Primary outcome
variable(s)

4,604

France;
2011–2016

Dalgaard et al.
(2018)25)
Gadsbøll et al.
(2017)26)

Sample
size

Apixaban: ↑ 2–43.5% ↓ 33.2–17.2%
Rivaroxaban: ↑
18.4–22.4%
↑ 10–52%

↑ 0–2% (of the Danish
population)
↑ 51–64.5%

↑ 20–22.3%

↑ From 4.8 Rivaroxaban: ↑ to 18% ↓ 99–67%
to 7 million Dabigatran: ↑ to 15% (2010–2014)
prescriptions Apixaban: ↑ to 7%
per year
↑ 52.4–60.7%
↑ 0–25.8%
↓ 52.4–34.8%
↑ 57–60%

↓ 56–28%

Likelihood of
being treated
with an OAC
increased with
time
↑ 0–75%
↑ 8.1–78.9%

(continued to the next page)
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Table 1. (Continued) Secular trends in prescriptions for atrial fibrillation
Country;
study period

Author (years)

Source

Sample
size

Secular trend over study period

Primary outcome
variable(s)

All OACs
combined

APA
monotherapy

NOAC

VKA

↑ 0–26%

↑ 13.6–9.6%

↑ 0–25.4% (2012–
2015)

↓ 36–26%

↓ 30.2–16.3%

↑ 0–9.5%

↑ 4–46.1%

Asia
Taiwan;
2008–2015

Taiwan national
health insurance
database
Korea;
National Health
2008–2015 Insurance Service
of Korea database
China (Yunnan
provence);
2001–2012

Chao et al.
(2018)37)
Lee et al.
(2017)38)
Guo et al.
(2015)39)
Countries combined
Verheugt et al.
(2018)40)
Haas et al.
(2019)41)

GARFIELD-AF
registry
GARFIELD-AF
registry

276,246
921

Proportion on OAC
↑ 13.6–35.6%
(CHA2DS2-VASc: ≥1 males
and ≥2 females)
Proportion prescribed OAC ↑ 34.7–50.6%
(CHA2DS2-VASc≥2)
OAC treatment initiated at
AF diagnosis
(CHA2DS2-VASc≥2)

l
a

51,270

↑ 8–55%

OAC or APA treatment
↑ 42.1–57.7%
↓ 30.2–16.3%
initiated at AF diagnosis
24,137
NOAC prescription in
↑ 33.8–62.6%
newly diagnosed AF
(CHA2DS2VASc≥2)
AF = atrial fibrillation; APA = antiplatelet agent; GARFIELD-AF = global anticoagulant registry in the field-atrial fibrillation; NCDR PINNACLE = national
cardiovascular data registry's practice innovation and clinical excellence; NOAC = non-vitamin K antagonist; OAC = oral anticoagulant; ORBIT-AF = outcomes
registry for better informed treatment of atrial fibrillation; VKA = vitamin K antagonist.

n
o

i
is

v
o

as monotherapy to reduce stroke risk, there still remains a significant proportion of high-risk
patients (approximately 30%) that are receiving inappropriate APA thromboprophylaxis for
reducing stroke risk.

r
P
Prescription (%)
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Studies of prescription registry data and time-series analyses in multiple countries over the
past decade have consistently shown that NOACs emerged as the favoured anticoagulant
toward the end of the past decade (Figure 2 and Table 1).22)24)26-28)30-32)37) NOACs were released

Warfarin

100

l
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Secular trends in non-vitamin K antagonist oral anticoagulants over the past
decade
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Norway (Urbaniak et al. (2017)28))
Denmark (Gadsbøll et al. (2017)26))
Denmark (Sindet-Pedersen et al. (2018)29))

France (Maura et al. (2019)24))
United Kingdom (Apenteng et al. (2018)19))
United Kingdom (Martinez et al. (2016)56))

USA (Zhu et al. (2018)36))
USA (Thompson et al. (2017)34))
USA (Marzec et al. (2017)33))

Figure 2. Secular trends of warfarin versus NOACs.
NOAC = non-vitamin K antagonist oral anticoagulant.
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in the market between 2010 and 2013 in the USA, Western Europe, and Korea. Studies in
these countries have shown that in the first 1–2 years after their release, the proportion of
high-risk patients that were prescribed NOACs increased from <2% to 25–33%.21)33)36)38)
A study in the USA that has followed up for five years after the introduction of NOACs
showed that an even higher proportion (75%) of high-risk patients were prescribed a NOAC
when diagnosed with AF. The relative use of this class of anticoagulants is of course also
determined by the level of government subsidization of their cost, which can be minimal or
absent in low- and middle-income countries, where the cost of NOACs may be beyond the
reach of most elderly patients with AF.
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P
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A number of studies have examined clinician's prescribing behaviours after the introduction
of NOACs. In the period immediately following NOAC release, patients prescribed this
class generally had lower stroke and bleeding risks compared with those treated with
warfarin.17)19)33) Other studies showed that patients with certain risk factors represented in the
CHA2DS2-VASc score, such as advanced age, vascular disease, HF, male gender and diabetes
were also less likely to be prescribed NOACs.17)33) There is a growing body of research that is
suggesting that clinicians have improved their prescribing of NOACs to more closely follow
guidelines in more recent years.19)23)26)33) However, perceived higher bleeding risk of NOACs
is still reported by clinicians to be a barrier to their use,8)10) despite warfarin and NOACs
having relatively similar bleeding risk profiles, with the marked exception of intracranial
hemorrhage.9) There is also some evidence suggesting that specialists and sub-specialists,
such as cardiologists and electrophysiologists, are more inclined to prescribe NOACs in
preference to warfarin compared to primary care physicians.36)42)

l
a

n
o

A number of factors may contribute to these trends. Several contraindications to NOACs that
are associated with CHA2DS2-VASc score, such as renal impairment and valvular heart disease
may coexist among patients with higher CHA2DS2-VASc scores, although a recent metaanalysis of NOAC use in chronic kidney disease suggests this class is safer than VKA.43) There
was no anticoagulation reversal for bleeding available for NOACs when they were released
on the market, therefore clinicians may have been less inclined to prescribe them to patients
with higher bleeding risk. This is despite evidence from the pivotal randomised trials which
showed that NOACs were safer after a major bleed than VKAs in the absence of a reversal
agent which was available for VKA. Furthermore, clinicians (and especially non-specialised
clinicians) may lack familiarity and experience with prescribing NOACs and may choose
to stay with agents with which they are more familiar, comfortable and knowledgeable.
This has been one area of focus in quality improvement activities for clinicians,44) but also a
focus of the promotion and marketing activities by pharmaceutical companies following the
development of reversal agents such as idarucizumab and andexanet alpha and their release
to the market.45)46) To date, there is no compelling evidence suggesting clinicians favour one
NOAC over another, and prescribing of specific NOACs seems to be largely driven by country
and regional factors in availability, promotion, or reimbursment.17)
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Summary of the secular trends in the management of stroke risk among
patients with atrial fibrillation
Multiple studies from several countries support that the clinical management of AF to reduce
stroke risk with thromboprophylaxis has progressively improved over the past decade, in
response to promotion of changes in AF management guidelines, various practice incentives,
perceived ease of use of NOACs and strong marketing by pharmaceutical companies which
produce NOACs during the same time frame. This has been strikingly mirrored by a declining
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incidence of AF-related stroke.21)37)44) Newly-diagnosed patients with intermediate/high
stroke risk are increasingly more likely to receive guideline-recommended therapy. But the
higher rates are not uniform, and remain low in a number of countries. There has also been
a notable decrease in the use of APAs to reduce stroke risk, the one exception being China,
which showed an increased use of aspirin over the past decade.39)47) The transition from
the CHADS2 to CHA2DS2-VASc for stroke risk assessment has increased the proportion of
patients deemed to be at higher risk during this period. The relative ease-of-use and fewer
contraindications and interactions certainly played a major role in their uptake by physicians
prescribing them as first-line therapy.
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There remains a significant proportion of high-risk patients that are being treated with APAs
alone, which are markedly less effective than OACs, relatively ineffective in preventing large
cardio-embolic stroke, but still have appreciable major bleeding risks. There is also a sizeable
proportion of low-risk patients inappropriately receiving anticoagulation therapy. On the
positive side, the most important example of the impact of the favourable secular trend in
appropriate prescription has been in the United Kingdom. Increase in appropriate OAC
prescription to 78% from the 2009 level, and decrease in antiplatelet use, has been predicted
to be associated with the prevention of 4,000 AF-related strokes in 2019 alone.12)21) It will take
some time to quantify how these changes in practice have translated into AF-related stroke
outcomes globally.
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PATIENT PERSISTENCE AND ADHERENCE WITH ORAL
ANTICOAGULANT THERAPY

n
o

Medication persistence is the act of continuing to take medications for the prescribed
treatment duration.48) In AF, this usually equates to lifelong treatment. Non-persistence
is defined as discontinuation of the medication, i.e. stopping the drug permanently. Nonpersistence is usually assumed when scripts are no longer filled after a specified grace period,
which varies in the literature from 30 to 90 days.
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In contrast, medication adherence refers more to patients taking the drug as prescribed;
relating to aspects such as timing, number of daily doses taken, and adhering to any required
dietary modifications.48) Adherence is commonly calculated from prescription databases
using the proportion of days covered (PDC) according to the prescribed medication dosage:
good adherence is usually defined as a PDC >0.80. The PDC accounts for daily doses that
may be missed and interruptions to therapy, however in some studies, those who have
discontinued their medication (i.e. absolute non-adherence) are also counted in the total
PDC. Therefore, direct comparison of both adherence and persistence rates between studies
is limited due to different definitions and methodologies for calculating these outcomes.

r
P

Impact of poor persistence and adherence
Although there has been an improvement in overall guideline-based prescription of OAC
over the past decade, prescription alone is not sufficient for effective stroke prevention in AF.
It is also pertinent that patients continue to take OAC medications long-term (persistence),
and take them as prescribed (adherence), however, a global problem exists with both patient
persistence and adherence which requires further exploration and attention. It seems obvious
that the benefits of OAC on stroke and mortality documented in randomized trials will not
be realised if the medication is not taken. This issue of poor persistence and adherence,
https://e-kcj.org
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however, is not widely appreciated to be a significant cause of AF-related stroke. A study of
data from the UK Clinical Practice Research Datalink demonstrated a high early stroke risk of
discontinuing OAC, which remained fairly constant over the following 3 years, leading to an
excess of 5 strokes in 3 years for every 100 people who stop OAC.49)
Good adherence, defined as PDC >0.80, is associated with reduced risk of all-cause
mortality (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.81–0.91) and ischaemic
stroke (HR, 0.69; CI, 0.56–0.85) as shown from data from the Valencia Health System
database in Spain (n=37,774).50) Conversely, poor adherence (PDC<0.80) at 12-month followup is associated with a significantly higher risk of both ischaemic stroke (HR, 2.08; CI,
1.11–3.88) and deep vein thrombosis (HR, 5.39; CI, 1.78–16.3).51) Further, it appears that the
degree of stroke and mortality risk is proportional to the degree of adherence. For each 0.10
decline in PDC for dabigatran there was an associated higher risk of mortality and stroke
(HR, 1.07; CI, 1.03–1.12). While the point estimate was identical for rivaroxaban, the trend
was non-significant (HR, 1.07; CI, 0.89–1.28).52) A similar association for dabigatran was
noted in a study using the USA Veterans Affairs database (n=5,376: there was an increase
in all-cause mortality and stroke (HR, 1.13; CI, 1.08–1.19) for each 0.10 decline in PDC.53)
Interestingly, when NOAC adherence is poor (PDC<0.80) the resulting increased ischaemic
stroke risk is similar for both NOACs taken once-daily (HR, 1.47; CI, 1.20–1.80) and those
taken twice-daily (HR, 1.50; CI, 1.23–1.83).54)
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The global issue of suboptimal persistence
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Persistence with OAC therapy appears to be a problem worldwide, with similar patterns of
decline noted across different countries (Figure 3).26)55-62) Once prescribed, a large proportion
of patients fill their initial OAC prescription, but persistence declines over time, with around
only half of patients still taking OAC therapy by 2 years. Discontinuation often seems to occur
quite early after initial prescription. USA health care claims data (n=16,253) showed the mean
time to discontinuation occurred at ~3.7 months; and after 2-years follow-up persistence with
warfarin was only 49%.63) Similar low persistence rates at 2-years were also noted in China
(43%)64) and Germany (48%).60)
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A gradual decline in persistence following initiation of OAC therapy has been noted in all
studies (Table 2).52)53)55-61)64-72) In Australia, the first prescription repeat was filled by 91% of
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Figure 3. Time-course of oral anticoagulant persistence.
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patients, reducing to 70% at 12-months, and 57% at 30-months.59) Similar declines were
noted in Scotland where persistence rates for NOACs were 76% at 12-months, and 70% after
18-months,58) and the United Kingdom with 2-year persistence rates dropping to ~70%.56)57)
The highest reported persistence rates overall came from the Stockholm administrative
health data register, which reported persistence for any OAC was 88% at 12-months and 83%
at 2-years,55) but these rates may be influenced by the definition of discontinuation, being any
script filled in the 6-month follow up period.55) However, there may be a cultural influence
as other Swedish studies have also identified high long-term persistence rates of 89% after
5-years.73) Self-reported discontinuation from the Chinese AF registry also identified similarly
high persistence rates for NOAC medications.61)
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Suboptimal adherence

It is more difficult to gauge if medications are actually taken once the prescription is filled.74)
Different methods can provide vastly differing results when calculating adherence and
persistence rates. In a study using the USA HealthCore Integrated Research Database (n=675)
adherence at 12-months was 48% using prescription refill data, and only 37% when measured
using self-report (the eight-item Morisky Medication Adherence Scale [MMAS-8]).75) This
could suggest that although people were filling their prescription they may not have actually
taken all the doses.76) Other studies using MMAS-8 survey data have also shown poor longterm adherence of only 55%.77)
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Most studies have utilised PDC to measure adherence. The majority of these studies are
cross-sectional, rather than looking at the time-course of adherence following treatment
initiation. The studies looking at adherence over time do show a reduction in adherence
to NOACs following treatment initiation (Table 2). Using PDC ≥0.80, data from the USA
Veterans Affairs Healthcare System (n=2,882) identified 72% adherence at 12-months.52)
Korea had similar rates for adherence to of NOACs of 87% measured with medication
possession ratio ≥0.8 using Health Insurance data (n=1,234).73)
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Comparison between oral anticoagulant medications

v
o

In the early 2000s persistence to warfarin was reported to be ~70% at 1-year and ~60% at
2-years.78-80) With the release of NOAC medications in the early 2010s, the generally-held
perception was that NOACs would result in better medication adherence and persistence,
in part due to the reduced need for monitoring, and dietary restrictions. Many studies have
reported higher persistence rates for NOACs, however some large studies published in the
last 4 years that have shown little difference between NOAC and VKA persistence (Table 2).
A meta-analysis of OAC medications from 2014 also identified no statistical difference in
persistence rates between VKA and NOAC.81)

r
P

A large study from Germany (n= 51,606) showed similar persistence at 12-months with
warfarin (70.1%) and NOACs (70.5%).67) Similarly, within a Stockholm study (n=17,741), at
12-months warfarin persistence (85%) was similar to apixaban (86%), and both were notably
higher than dabigatran (77%) and rivaroxaban (74%).55) In contrast, data from the United
Kingdom for 2011–2014 found higher persistence rates for NOACs compared with warfarin
at all time-points: 3-months (95% vs. 87%), 6-months (86% vs. 77%), 12-months (79%
vs. 64%), and 2-years (70% vs. 50%).56) Also, an Australian study from 2013–2015, found
persistence at 12-months was 70% for NOACs and 38% for warfarin: indicating patients on
warfarin were 2.5 times more likely to discontinue over 12-months than those on NOACs.69)
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Table 2. Time-course of persistence and adherence for oral anticoagulants from initiation of therapy
VKA (%)
Apixaban (%)
Rivaroxaban (%)
Dabigatran (%)
Country;
Sample
Measure
Study (years)
Source
Months
Months
Months
Months
study period
size
definition
3 6 12 24
3
6 12
24
3
6 12
24
3
6 12
24
Persistence
BeyerGermany; IMS® Disease
7,265
Supply gap
58 26
66 53
60 47
Westendorf
2012–2013
Analyzer
>60 days
et al. (2016)66)
Collings et al. Germany; IMS® Disease 15,244
Supply gap
94 71 58 49
79
72 63
59
82
67 57
49
71
60 50
42
(2017)60)
2012–2014
Analyzer
>60 days
Hohnloser
Germany;
Institute for
51,606
Supply gap
70
72
71
67
et al. (2019)67) 2013–2016 Applied Health
>30 days
Research
Forslund et al. Stockholm; Stockholm
17,741 Any script filled
85 78
86
77
69
74
66
(2016)55)
2011–2014 administrative
in 6-months
health data
period;
register
CHA2DS2VASc=2–9
Björck et al.
Sweden;
AuriculA
478
Not defined
91
(2016)68)
2010–2013
Swedish
national quality
register
Johnson et al.
UK;
Clinical practice 15,242
Supply gap
94 87 78 71
92
88 83
83
86
81 73
68
84
74 67
63
(2016)57)
2012–2014
research
>56–60 days
database
Martinez et al.
UK;
Clinical practice 27,514
Supply gap
87 77 64 50
(2016)56)
2011–2014
research
>30 days
database
Mueller et al.
Scotland;
Prescribing
5,398
Supply gap
87 86
84 79
75
68 60
55
(2017)58)
2011–2014 Information
>28 days
(18-months)
(18-months)
System
Simons et al.
Australia;
PBS records
1,471
Supply gap
86
38
(2016)69)
2013–2015
>90 days
Simons et al,
Australia;
PBS records
8,656
Supply gap
92
73
61
91
68
55
89
66
52
(2017)59)
2013–2016
>90 days or
(first repeat)
(30-months) (first repeat)
(30-months) (first repeat)
(30-months)
switching to
warfarin
Shiga et al.
Japan; Tokyo Women's
601 Discontinuation 93 88 82
90
83 80
88
83 70
80
76 65
(2015)70)
2011–2014
Medical
reported in
University
medical record
Hospital
Wang et al.
China;
Chinese AF
1,461 Self-reported 78
56 43
(2016)64)
2011–2014
registry
discontinuation
Liu et al.
China:
Chinese AF
5,699 Self-reported
93 89
(2019)61)
2011–2017
registry
discontinuation
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Table 2. (Continued) Time-course of persistence and adherence for oral anticoagulants from initiation of therapy
VKA (%)
Apixaban (%)
Rivaroxaban (%)
Dabigatran (%)
Country;
Sample
Measure
Study (years)
Source
Months
Months
Months
Months
study period
size
definition
3 6 12 24
3
6 12
24
3
6 12
24
3
6 12
24
Zalesak et al.
USA;
USA
5,145
Supply gap
53 39
72 63
(2013)71)
2010–2012 Department of
>60 days
Defence
Adherence
Borne et al.
USA;
Veterans Affairs 2,882
PDC>0.80
77
75
71
(2017)52)
2010–2015 Healthcare
System
Brown et al.
USA;
Truven Health 15,341
PDC>0.80
71
60
71
59
61
48
(2017)72)
2012–2014
Analytics
MarketScan
database
Han et al.
Korea;
HIRA service1,234
MPR≥0.80
92
84
88
(2019)65)
2014
aged patient
sample
Shore et al.
USA;
Veterans Affairs 5,376
PDC≥0.80
71
71
(2014)53)
2010–2012 Corporate Data
Warehouse
AF = atrial fibrillation; HIRA = Health Insurance Review and Assessment Service; MPR = medication possession ratio; PBS = pharmaceutical benefits scheme; PDC = proportion of days covered; VKA =
vitamin K antagonist.
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Overall, it appears that apixaban consistently achieves higher persistence rates than the
other OAC medications, with warfarin and rivaroxaban generally achieving similar rates,
and dabigatran overall achieving the lowest rates (Table 2). Higher persistence for apixaban
is noted across all time points, except for one German study which showed warfarin
persistence (94%) was higher than the NOACs at 3-months (mean 81%); however at
12-months apixaban had highest persistence (63%).60) Because apixaban was launched a few
years after dabigatran and rivaroxaban, comparative data have only been available relatively
recently, and it should be noted that in many of these analyses there were smaller numbers
treated with apixaban.
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This result of higher persistence with apixaban is somewhat surprising given that apixaban
is required to be taken twice-daily, compared to the once daily dosing of rivaroxaban. A
meta-regression of persistence to cardiac medications confirmed that people on twice-daily
dosages are 23% (CI, 13–33) less likely to have good persistence than those with once-daily
regimes.82) A large USA study (n=36,868) comparing NOACs noted higher adherence of
73% for once-daily dosing with edoxaban or rivaroxaban (combined), compared to 68%
for twice-daily dosing with apixaban or dabigatran (combined).54) However, as apixaban
users constituted only a quarter of the twice-daily population, and rates were not reported
separately for each medication and it is possible that those on apixaban may have also
achieved superior persistence in that study.
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Persistence and adherence to other medications

r
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Sub-optimal medication adherence is not unique to OACs. A review of USA claims data in
2010 noted only 72% of all new prescriptions were filled, in respect of all medications.74) In
this analysis, adherence with filling prescriptions was notably worse for chronic conditions
such as hypertension (filling rate: 72%), hyperlipidaemia (72%), and diabetes (69%).74) This is
consistent with low rates of adherence to cardiac medications. Following myocardial infarction,
when it could be assumed that motivation to take medications should be high, adherence with
taking medications was only 57%.83) In this myocardial infarction sample (n=405) from the
USA, the factors associated with lower adherence were younger age, lower education, lower
financial stability, and concerns about medication side effects.83) Although race has not been
identified as a factor related to adherence, it was noted that African Americans were less likely
to follow instructions on how to take their medications.84)
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Patient beliefs about cardiac medications and treatment were identified as a major theme in
an Australian review, where adherence with cardiac medications was recorded as 57–86%.85)
In comparison, self-reported adherence with cardiac medications was better in Japan at
83%.86) Interestingly, in that study ‘forgetting’ to take medications was the most common
reason for poor adherence, and this was most likely to occur for medications requiring
≥2 dosages per day, younger age, and those employed (especially those with a busy work
schedule).86)

Factors associated with oral anticoagulant adherence and persistence
Overall, OAC adherence rates appear to be comparable to adherence rates for chronic and
cardiac conditions. Therefore, multiple patient-level factors may be contributing to poor
adherence and persistence in addition to specific OAC-related factors (e.g. fear of bleeding,
difficulty with monitoring and INR testing, and dietary restrictions related to warfarin).
General factors affecting both OAC adherence and persistence should be assessed in each
patient, with consideration of both ‘lifestyle’ and ‘intrinsic’ factors (Box 1).
https://e-kcj.org
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Box 1: Factors that may be associated with poor adherence and persistence
Medical factors:
No prior history of stroke/TIA; or low stroke risk
Less comorbidities
High bleeding risk
Paroxysmal AF; or lack of AF symptoms
Electrical cardioversion after commencing OAC
≥2 dosages per day
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Patient factors:
Younger age
Lower health literacy
Low AF knowledge; unaware of associated stroke risk
Poor OAC knowledge
Medication concerns (bleeding and lifestyle related)
Information overload
Anger, depression or anxiety from the AF diagnosis
Low treatment satisfaction
Busy work schedule
No health insurance cover; low ability to pay for medications
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Age

Most research indicates a clear association between older age (≥65 years) and better
adherence63)72)77)87) and persistence to OAC therapy.52)67)71) A stepwise trend was noted for
better persistence with increasing age: 65–74 years HR, 0.95 (CI, 0.88–1.03), 75–84 years
HR, 0.77 (CI, 0.71–0.83), and 85+ years HR, 0.64 (CI, 0.58–0.71).67) In a large USA study
(n=15,341) using the MarketScan database, adherence was also noted to strengthen over
time since initial prescription.72) Compared to those younger age groups, for people aged
65–74 years the odds ratio (OR) for better adherence was 2.94 (CI, 2.66–3.24) at 3-months,
3.60 (CI, 3.27–3.97) at 6-months, and 5.43 (CI, 4.89–6.04) at 12-months.72) Only one study
contrasted these results. Data from the German IMS® Disease Analyzer (n=7,265) indicated
that increasing age was associated with poorer persistence, with an OR, 0.99 (CI, 0.98–0.99)
per extra year of age.66)
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Sex

There is no clear association seen between sex and OAC persistence. One German study
(n=7,265) suggested male sex was associated with better persistence rates: OR, 1.11 (CI, 1.01–
1.23).66) In contrast, a larger German study (n=51,606) reported male sex was associated with
higher rates of discontinuation: HR, 1.12 (CI, 1.06–1.18).67) This lower persistence in men was
supported by an Australian survey which identified women were more likely to comply with
their medication regime than men OR, 1.69 (CI, 1.08–2.63).77)

Co-morbidities
In general, people with additional medical co-morbidities are more likely to have higher
adherence and persistence to OAC therapy, especially those with comorbidities related to
an increased stroke risk.52)63)64)71) Results obtained in Germany and the USA showed similar
https://e-kcj.org
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associations with higher persistence for the presence of hypertension OR, 1.19–1.23 and
diabetes OR, 1.21–1.24.66)72) Additional associations likely to improve persistence included
dyslipidaemia OR, 1.21 (CI, 1.12–1.31) and cancer OR, 1.28 (1.12–1.48).66)72) Further, people
were less likely to discontinue OAC if they also had congestive HF (HR, 0.90; CI, 0.85–0.96)
or peripheral artery disease (HR, 0.89; CI, 0.81–0.97).67) As expected, those with a prior
history of stroke/ TIA were much less likely to discontinue OAC (OR, 0.36; CI, 0.2–0.68),52)
and those without prior stroke/TIA have higher likelihood of discontinuing (HR, 1.60; CI,
1.24–2.05).52)64)
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Conversely, those with a higher bleeding risk were more likely to discontinue (HR, 1.25; CI,
1.08–1.46), as well as those with a history of intracranial bleeds (HR, 3.61; CI, 1.80–7.25).71)
Other factors associated with a higher likelihood to discontinue are paroxysmal AF (HR, 1.56;
CI, 1.28–1.92), where both doctors and patients may not perceive a significant risk if they are
mostly in sinus rhythm64) and absence of AF symptoms.88)
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Health insurance and financial circumstances

i
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The presence of health insurance is an importance consideration in OAC persistence.64)66)
In China, people without insurance cover are more likely to discontinue (HR, 1.65; CI,
1.03–2.64).64) Similarly, the presence of health insurance led to better persistence rates
with an OR, 1.22 (CI, 1.03–1.44) according to German IMS® Disease Analyzer data.66) Lower
socio-economic status and capacity to afford medications, significantly impacts ability to fill
prescriptions,89) and adherence is known to be lower for medications that cost more.77) Other
research from the USA, has identified income and social support as known variables affecting
medication taking as a whole.84)
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Health literacy, atrial fibrillation knowledge, and oral anticoagulant knowledge
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Intrinsic patient factors such as core beliefs, health literacy, cognition, and medication
awareness, can significantly alter the patient's decisions about taking medications.90)91)
If correctly identified, these factors can be addressed and overcome with appropriate
interventions.90)91) Health literacy, and knowledge of AF are significant predictors of
medication adherence in AF.77)88)92)93) As a specific example, 21.7% of patients, in a Chinese
study, declined to take the prescribed OAC because they were not informed of the stroke risk
associated with AF.94)
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Greater OAC knowledge was highly associated with better adherence (OR, 1.60; CI, 1.12–
2.30)88); especially in relation to better understanding of risk-benefit, bleeding risk and how
this impacts their quality of life.89) A belief in the importance of OAC medications increases
adherence, and strong negative beliefs or fears around OAC medications (especially the
perceived adverse effects of warfarin) lead to poor adherence.93) Despite these concerns, a
systematic review has shown appropriate education can overcome barriers regarding fear
of bleeding, resulting in the majority being willing to accept an increased bleeding risk to
reduce the risk of a stroke.95) However, education needs to be correctly targeted to individual
patients, as information overload can led to poorer adherence.77)

Personal well-being, lifestyle and employment
Treatment satisfaction is associated with better adherence (OR, 1.05; CI, 1.00–1.09).77)88)
Emotions of anger, depression, or anxiety resulting from the AF diagnosis reduce adherence
and persistence.87)96) Furthermore, it is also reported that impaired memory, family
situations, support available, and busy work schedules all affect adherence.89)
https://e-kcj.org
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Factors impacting adherence are often related to lifestyle choices.90)91) Particularly in the
young and middle-aged, non-adherence may result from the demands of work, social
activities and commitments.93)97) People who are employed are more likely to have lower
OAC adherence compared to those who are unemployed.77) Thus, time commitments are an
important consideration, and medication regimes with fewer daily doses are shown to have
higher adherence.97) These factors can easily be overlooked during a consultation, however,
it is important to consider the patient's well-being and personal circumstances in order to
determine the pertinent factors impacting medication adherence and persistence.

How to improve oral anticoagulant adherence and persistence in practice
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Health professionals have a pivotal role in assessing and maximising medication adherence
and persistence among their patients. The critical role of monitoring OAC persistence has
recently been highlighted by the European Heart Rhythm Association (EHRA) (Box 2).91) EHRA's
practical guide for OACs in AF advocates for 3-monthly follow-up to review persistence.91) The
guide recommends multiple strategies to achieve optimal adherence and persistence, including:
adequate patient education; involvement of family members; pre-specified follow-up schedules;
involving a local pharmacist if possible; use of technical aids (medication boxes, phone apps,
reminder systems); and electronic monitoring if poor adherence is suspected.91) The new
Australian AF management guidelines have also recommended similar strategies and note
that specific attention should be paid to patient persistence.9) The Australian guidelines also
recommend the development of individualised strategies to increase adherence and persistence,
and recognise the need for patient-centred care and decision-making in this process.9)
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An important intervention effect was observed in the IMPACT-AF cluster-randomised
controlled trial which assessed the effect of targeted education of providers, patients and
families.98) In that study, significantly higher proportions of patients were appropriately
prescribed OAC in the intervention group at 6-months and 1-year.98) However, the AEGEAN
study looked at the effect of additional education on adherence to apixaban over 48 weeks,
however failed to find an improvement.99) Patients were randomised to standard care only,
or standard care plus an education package which included a selection of reminder apps
and access to a virtual clinic.99) Both groups were followed up every 12-weeks to determine
medication adherence, and at 48 weeks there was no difference between additional education
and standard care (90.4% vs. 90.1%).99) This high adherence in both groups may be the result
of regular follow-up, which was also observed in a smaller study in Belgium.100) Potentially,
attention to individual patient factors may have further improved adherence rates, however it
would be difficult to improve on 90% adherence.
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Box 2: European Heart Rhythm Association recommendations to improve
oral anticoagulant persistence
Adequate patient education
Involvement of family members
3-monthly review
Pre-specified follow-up schedule
Involve local pharmacist if possible
Technical aids (medication boxes, phone apps, reminder systems)
Electronic monitoring if poor persistence suspected
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Patient-centred approach
It is suggested that a good physician-patient relationship and communication is required to
facilitate good patient adherence and persistence with OACs.101) Patients want to be involved
in the decision-making process, and wish to feel reassured about the diagnosis, understand
the condition sufficiently, and understand the possible side effects of OAC medications.96)
At each follow-up visit, health professionals should assess patient knowledge of AF, OAC
risk-benefit and bleeding risk, and check on the patient's current priorities and concerns,
and how treatment may impact their quality of life.89)101) It is important to determine any
barriers impacting taking medications, including the patient's cognition and memory, and
understand the facilitators and assistance that is available to each patient.89) Facilitators that
should be considered include their family situation and any support systems available to
them.89) Establishing an appropriate medication routine or system is important, and this can
improve both adherence and persistence.102)

n
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Family and carer involvement

i
is

Involvement of family and caregivers in the development of medication strategies
significantly improves adherence.103) Valuable insights can be identified through discussions
with family, especially in relation to successful methods for medication management
and suitability of alternative strategies and assistance (e.g. Webster packs, pillboxes, and
reminders).103) Family can also provide important information pertaining to difficulties or
challenges faced by the patient, and relevant beliefs or medication concerns.
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Atrial fibrillation knowledge and decision aids

If underlying knowledge deficits exist, or if there are significant beliefs that medications have
negative side-effects, medication strategies may not be effective. Additionally, as cognitive
impairment is common in patients with AF,104) education and intervention strategies may
need to be altered to accommodate the patient's knowledge and/or cognitive deficits. To
ensure the information is understood and knowledge is retained, it is important to consider
the timing, delivery and choice of education materials. Decision aids for patient education
have been shown to improve knowledge and acceptance of treatment and medications,
resulting in increased adherence rates.105) These aids could be incorporated into AF
education, however it is essential to consider the patient perspective during this process.89)
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Electronic reminders and apps
Assistance required by younger people will generally differ from that required by older
populations. In a younger population, where forgetting to take medications can be a primary
cause of poor adherence, especially due to busy work or social schedules, reminders and
systems are likely to assist. However, if the adherence issue is more deeply related to anxiety,
medication concerns, a fear of bleeding or impact on activities of daily living, then reminders
and alerts are unlikely to work, and a different approach is warranted.
A meta-analysis of text messaging studies for medication adherence in people with chronic
disease showed that text messages significantly improved medication adherence (OR, 2.11;
CI, 1.52–2.93).106) However these text studies generally included younger people with a mean
age of 39 years (range, 31–64 years).106)
Medication apps have been shown to significantly increase adherence to cardiac medications
compared to usual care in a middle-to-older age sample (mean age, 58 years).107) Medication
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apps are often divided into 1) basic apps using reminder strategies only, such as alarms
and push notifications; and 2) more advanced apps using behavioural and educational
strategies.108) Advanced apps often use behavioural strategies such as external monitoring,
personal tracking, and gamification.108) These advanced apps often include additional
features such as tracking of health metrics, appointment reminders, refill reminders, ability
to record medical history, and pharmacy information.108) However, a recent randomised
control study identified no difference in medication adherence rates between the basic and
advanced apps.107)

l
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Electronic monitoring

Electronic monitoring tools provide real-time monitoring of exact medication taking
behaviour and provide this information to the health professional. They are particularly
useful for pinpointing patterns of poor adherence.109) Although more expensive than other
options, these interventions have been shown to be successful for people with very poor
adherence. A systematic review of electronic monitoring tools demonstrated a positive
improvement in medication adherence with use of these tools, over follow-up periods
ranging from 7- to 26-weeks.110)
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These systems use electronic sensors which transmit to a receiver and record information
on the exact time medications are taken.111) Available tools include ‘smart pill boxes’ which
record lid opening; ‘wearable sensors’ which work in conjunction with smart pill boxes
and detect actions such as hand-to-mouth movements and pill swallowing; ‘ingestible
biosensors’ detecting pill ingestion; ‘computer vision’ which can detect medications
presence through images captured by the camera; and ‘radio frequency identification’
systems which communicate with a device (e.g. smartphone) in close proximity, and
provide an alert, such as a flashing light, when medications need to be taken.111) The
ideal tool needs to be determined with consideration given to the patient's personal
circumstances and needs.
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In conclusion, the management of stroke risk among patients with AF has been a rapidlyevolving area over the past decade. The review findings show that clinicians' management is
increasingly reflecting guideline recommendations, with a greater proportion of high-risk
patients (CHA2DS2-VASc≥2 men; ≥3 women) receiving OACs over the past decade. However,
there is still significant room for improvement in management, as 25–35% of high-risk
patients are still not prescribed OAC. Since the introduction of NOACs between 2010–2014 in
most countries, and guideline preference for NOAC as first line therapy for high-risk patients,
clinicians are prescribing NOACs in preference to warfarin.
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Despite better prescription, patient persistence and adherence with OACs long term is
poor, with 2-year persistence as low as 50% in many countries. In addition to OAC-related
factors such as a fear of bleeding, difficulty with monitoring, and dietary restrictions
related to warfarin; multiple other patient-level factors exist which contribute to poor
adherence and persistence. A detailed review of each patient, and better understanding of
the factors impacting adherence, will assist to direct appropriate interventions to improve
both adherence and persistence and reduce stroke-risk. Overall, the results highlight the
interplay of both clinician's awareness of guideline recommendations and understanding
of the individual patient level factors in reducing the population prevalence of stroke
attributable to AF.

https://e-kcj.org

https://doi.org/10.4070/kcj.2019.0234

18/25

Anticoagulation Prescription and Persistence

REFERENCES
1. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted
County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation
2006;114:119-25.
PUBMED | CROSSREF

2. Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors,
and mortality in the Framingham Heart Study: a cohort study. Lancet 2015;386:154-62.
PUBMED | CROSSREF

3. Andersson T, Magnuson A, Bryngelsson IL, et al. All-cause mortality in 272,186 patients hospitalized
with incident atrial fibrillation 1995–2008: a Swedish nationwide long-term case-control study. Eur Heart J
2013;34:1061-7.

l
a

PUBMED | CROSSREF

4. Healey JS, Oldgren J, Ezekowitz M, et al. Occurrence of death and stroke in patients in 47 countries 1 year
after presenting with atrial fibrillation: a cohort study. Lancet 2016;388:1161-9.

n
o

PUBMED | CROSSREF

5. Madhavan M, Hu TY, Gersh BJ, et al. Efficacy of warfarin anticoagulation and incident dementia in a
community-based cohort of atrial fibrillation. Mayo Clin Proc 2018;93:145-54.
PUBMED | CROSSREF

i
is

6. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med
2012;366:120-9.
PUBMED | CROSSREF

v
o

r
P

7. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who
have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67.

l
a

PUBMED | CROSSREF

8. Leung LY, McAllister M, Selim M, Fisher M. Factors influencing oral anticoagulant prescribing practices
for atrial fibrillation. J Stroke 2017;19:232-5.
PUBMED | CROSSREF

n
o

9. NHFA CSANZ Atrial Fibrillation Guideline Working Group, Brieger D, Amerena J, et al. National
heart foundation of Australia and the cardiac society of Australia and New Zealand: Australian clinical
guidelines for the diagnosis and management of atrial fibrillation 2018. Heart Lung Circ 2018;27:1209-66.

i
is

PUBMED | CROSSREF

10. Kjerpeseth LJ, Ellekjær H, Selmer R, Ariansen I, Furu K, Skovlund E. Risk factors for stroke and choice of
oral anticoagulant in atrial fibrillation. Eur J Clin Pharmacol 2018;74:1653-62.
PUBMED | CROSSREF

11. Gieling EM, van den Ham HA, van Onzenoort H, et al. Risk of major bleeding and stroke associated with
the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients
with atrial fibrillation: a cohort study. Br J Clin Pharmacol 2017;83:1844-59.

v
o

PUBMED | CROSSREF

r
P

12. Ben Freedman S, Gersh BJ, Lip GY. Misperceptions of aspirin efficacy and safety may perpetuate
anticoagulant underutilization in atrial fibrillation. Eur Heart J 2015;36:653-6.
PUBMED | CROSSREF

13. Joung B, Lee JM, Lee KH, et al. 2018 Korean guideline of atrial fibrillation management. Korean Circ J
2018;48:1033-80.
PUBMED | CROSSREF

14. Manav S. Contemporary management of stroke prevention in atrial fibrillation following the European
Society of Cardiology guidelines. Eur Cardiol 2017;12:38-9.
PUBMED | CROSSREF

15. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with
atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force
on practice guidelines and the heart rhythm society. J Am Coll Cardiol 2014;64:e1-76.
PUBMED | CROSSREF

16. Lip GY, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and
expert panel report. Chest 2018;154:1121-201.
PUBMED | CROSSREF

17. Steinberg BA, Shrader P, Thomas L, et al. Factors associated with non-vitamin K antagonist oral
anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: results from the outcomes
registry for better informed treatment of atrial fibrillation II (ORBIT-AF II). Am Heart J 2017;189:40-7.
PUBMED | CROSSREF

https://e-kcj.org

https://doi.org/10.4070/kcj.2019.0234

19/25

Anticoagulation Prescription and Persistence

18. von Schéele B, Fernandez M, Hogue SL, Kwong WJ. Review of economics and cost-effectiveness analyses of
anticoagulant therapy for stroke prevention in atrial fibrillation in the US. Ann Pharmacother 2013;47:671-85.
PUBMED | CROSSREF

19. Apenteng PN, Gao H, Hobbs FR, Fitzmaurice DA; UK GARFIELD-AF Investigators and GARFIELD-AF
Steering Committee. Temporal trends in antithrombotic treatment of real-world UK patients with newly
diagnosed atrial fibrillation: findings from the GARFIELD-AF registry. BMJ Open 2018;8:e018905.
PUBMED | CROSSREF

20. Camm AJ, Pinto FJ, Hankey GJ, Andreotti F, Hobbs FD; Writing Committee of the Action for Stroke
Prevention alliance. Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in
practice: barriers to and strategies for optimal implementation. Europace 2015;17:1007-17.
PUBMED | CROSSREF

l
a

21. Cowan JC, Wu J, Hall M, Orlowski A, West RM, Gale CP. A 10 year study of hospitalized atrial fibrillationrelated stroke in England and its association with uptake of oral anticoagulation. Eur Heart J 2018;39:2975-83.
PUBMED | CROSSREF

22. Protty MB, Hayes J. Dawn of the direct-acting oral anticoagulants: trends in oral anticoagulant prescribing
in Wales 2009–2015. J Clin Pharm Ther 2017;42:132-4.

n
o

PUBMED | CROSSREF

23. Robson J, Dostal I, Mathur R, et al. Improving anticoagulation in atrial fibrillation: observational study in
three primary care trusts. Br J Gen Pract 2014;64:e275-81.

i
is

PUBMED | CROSSREF

24. Maura G, Billionnet C, Drouin J, Weill A, Neumann A, Pariente A. Oral anticoagulation therapy use in
patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants:
findings from the French healthcare databases, 2011–2016. BMJ Open 2019;9:e026645.

v
o

r
P

PUBMED | CROSSREF

l
a

25. Dalgaard F, Ruwald MH, Lindhardt TB, Gislason GH, Torp-Pedersen C, Pallisgaard JL. Patients with atrial
fibrillation and permanent pacemaker: temporal changes in patient characteristics and pharmacotherapy.
PloS one 2018;13:e0195175.
PUBMED | CROSSREF

n
o

26. Gadsbøll K, Staerk L, Fosbøl EL, et al. Increased use of oral anticoagulants in patients with atrial
fibrillation: temporal trends from 2005 to 2015 in Denmark. Eur Heart J 2017;38:899-906.
PUBMED

i
is

27. Gülker JE, Kröger K, Kowall B, Dingelstadt M, Stang A. Increasing use of anticoagulants in Germany and
its impact on hospitalization for intracranial bleeding. Circ Cardiovasc Qual Outcomes 2018;11:e004470.
PUBMED | CROSSREF

28. Urbaniak AM, Strøm BO, Krontveit R, Svanqvist KH. Prescription patterns of non-vitamin K oral
anticoagulants across indications and factors associated with their increased prescribing in atrial fibrillation
between 2012–2015: a study from the Norwegian prescription database. Drugs Aging 2017;34:635-45.

v
o

PUBMED | CROSSREF

29. Sindet-Pedersen C, Staerk L, Lamberts M, et al. Use of oral anticoagulants in combination with
antiplatelet(s) in atrial fibrillation. Heart 2018;104:912-20.

r
P

PUBMED | CROSSREF

30. Haastrup SB, Hellfritzsch M, Rasmussen L, Pottegård A, Grove EL. Use of non-vitamin K antagonist oral
anticoagulants 2008–2016: a Danish nationwide cohort study. Basic Clin Pharmacol Toxicol 2018;123:452-63.
PUBMED | CROSSREF

31. Pilote L, Eisenberg MJ, Essebag V, et al. Temporal trends in medication use and outcomes in atrial
fibrillation. Can J Cardiol 2013;29:1241-8.
PUBMED | CROSSREF

32. Weitz JI, Semchuk W, Turpie AG, et al. Trends in prescribing oral anticoagulants in Canada, 2008–2014.
Clin Ther 2015;37:2506-2514.e4.
PUBMED | CROSSREF

33. Marzec LN, Wang J, Shah ND, et al. Influence of direct oral anticoagulants on rates of oral anticoagulation
for atrial fibrillation. J Am Coll Cardiol 2017;69:2475-84.
PUBMED | CROSSREF

34. Thompson LE, Maddox TM, Lei L, et al. Sex differences in the use of oral anticoagulants for atrial
fibrillation: a report from the national cardiovascular data registry (NCDR®) PINNACLE registry. J Am
Heart Assoc 2017;6:e005801.
PUBMED | CROSSREF

35. Lubitz SA, Khurshid S, Weng LC, et al. Predictors of oral anticoagulant non-prescription in patients with
atrial fibrillation and elevated stroke risk. Am Heart J 2018;200:24-31.
PUBMED | CROSSREF

https://e-kcj.org

https://doi.org/10.4070/kcj.2019.0234

20/25

Anticoagulation Prescription and Persistence

36. Zhu J, Alexander GC, Nazarian S, Segal JB, Wu AW. Trends and variation in oral anticoagulant choice in
patients with atrial fibrillation, 2010–2017. Pharmacotherapy 2018;38:907-20.
PUBMED | CROSSREF

37. Chao TF, Chiang CE, Lin YJ, et al. Evolving changes of the use of oral anticoagulants and outcomes in
patients with newly diagnosed atrial fibrillation in Taiwan. Circulation 2018;138:1485-7.
PUBMED | CROSSREF

38. Lee SR, Choi EK, Han KD, Cha MJ, Oh S, Lip GY. Temporal trends of antithrombotic therapy for stroke
prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist
oral anticoagulants: a nationwide population-based study. PLoS One 2017;12:e0189495.
PUBMED | CROSSREF

39. Guo Y, Wang H, Tian Y, Wang Y, Lip GY. Time trends of aspirin and warfarin use on stroke and bleeding
events in Chinese patients with new-onset atrial fibrillation. Chest 2015;148:62-72.

l
a

PUBMED | CROSSREF

40. Verheugt FW, Gao H, Al Mahmeed W, et al. Characteristics of patients with atrial fibrillation prescribed
antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF
registry. Eur Heart J 2018;39:464-73.

n
o

PUBMED | CROSSREF

41. Haas S, Camm AJ, Bassand JP, et al. Predictors of NOAC versus VKA use for stroke prevention in patients
with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Am Heart J 2019;213:35-46.

i
is

PUBMED | CROSSREF

42. Bastida C, Corominas N, Sotoca JM, Rovira M. Anticoagulation in atrial fibrillation: NOAC prescribing in
primary health care. Int J Clin Pharm 2017;39:478-82.
PUBMED | CROSSREF

43. Ha JT, Neuen BL, Cheng LP, et al. Benefits and harms of oral anticoagulant therapy in chronic kidney
disease: a systematic review and meta-analysis. Ann Intern Med. 2019 [Epub ahead of print].

v
o

r
P

l
a

PUBMED | CROSSREF

44. Freedman B. Major progress in anticoagulant uptake for atrial fibrillation at last: does it translate into
stroke prevention? Eur Heart J 2018;39:2984-6.

n
o

PUBMED | CROSSREF

45. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl
J Med 2017;377:431-41.

i
is

PUBMED | CROSSREF

46. Connolly SJ, Crowther M, Eikelboom JW, et al. Full study report of andexanet alfa for bleeding associated
with factor Xa inhibitors. N Engl J Med 2019;380:1326-35.
PUBMED | CROSSREF

47. Soo Y, Chan N, Leung KT, et al. Age-specific trends of atrial fibrillation-related ischaemic stroke and
transient ischaemic attack, anticoagulant use and risk factor profile in Chinese population: a 15-year
study. J Neurol Neurosurg Psychiatry 2017;88:744-8.

v
o

PUBMED | CROSSREF

48. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions.
Value Health 2008;11:44-7.

r
P

PUBMED | CROSSREF

49. Freedman SB, Martinez C, Wallenhorst C, Katholing A. High burden of potentially avoidable stroke from
discontinuation of warfarin therapy in non-valvular atrial fibrillation. Eur Heart J 2015;36:862.
50. Hurtado-Navarro I, García-Sempere A, Rodríguez-Bernal C, Santa-Ana-Tellez Y, Peiró S, Sanfélix-Gimeno
G. Estimating adherence based on prescription or dispensation information: impact on thresholds and
outcomes. a real-world study with atrial fibrillation patients treated with oral anticoagulants in Spain.
Front Pharmacol 2018;9:1353.
PUBMED | CROSSREF

51. Deshpande CG, Kogut S, Laforge R, Willey C. Impact of medication adherence on risk of ischemic stroke,
major bleeding and deep vein thrombosis in atrial fibrillation patients using novel oral anticoagulants.
Curr Med Res Opin 2018;34:1285-92.
PUBMED | CROSSREF

52. Borne RT, O'Donnell C, Turakhia MP, et al. Adherence and outcomes to direct oral anticoagulants among
patients with atrial fibrillation: findings from the veterans health administration. BMC Cardiovasc Disord
2017;17:236.
PUBMED | CROSSREF

53. Shore S, Carey EP, Turakhia MP, et al. Adherence to dabigatran therapy and longitudinal patient
outcomes: insights from the veterans health administration. Am Heart J 2014;167:810-7.
PUBMED | CROSSREF

https://e-kcj.org

https://doi.org/10.4070/kcj.2019.0234

21/25

Anticoagulation Prescription and Persistence

54. Alberts MJ, Peacock WF, Fields LE, et al. Association between once- and twice-daily direct oral anticoagulant
adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke. Int J Cardiol 2016;215:11-3.
PUBMED | CROSSREF

55. Forslund T, Wettermark B, Hjemdahl P. Comparison of treatment persistence with different oral
anticoagulants in patients with atrial fibrillation. Eur J Clin Pharmacol 2016;72:329-38.
PUBMED | CROSSREF

56. Martinez C, Katholing A, Wallenhorst C, Freedman SB. Therapy persistence in newly diagnosed nonvalvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost 2016;115:31-9.
PUBMED | CROSSREF

57. Johnson ME, Lefèvre C, Collings SL, et al. Early real-world evidence of persistence on oral anticoagulants
for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care. BMJ Open
2016;6:e011471.

l
a

PUBMED | CROSSREF

58. Mueller T, Alvarez-Madrazo S, Robertson C, Bennie M. Use of direct oral anticoagulants in patients with
atrial fibrillation in Scotland: applying a coherent framework to drug utilisation studies. Pharmacoepidemiol
Drug Saf 2017;26:1378-86.

n
o

PUBMED | CROSSREF

59. Simons LA, Ortiz M, Freedman B, Waterhouse BJ, Colquhoun D. Medium- to long-term persistence with
non-vitamin-K oral anticoagulants in patients with atrial fibrillation: Australian experience. Curr Med Res
Opin 2017;33:1337-41.

i
is

PUBMED | CROSSREF

60. Collings SL, Lefèvre C, Johnson ME, et al. Oral anticoagulant persistence in patients with non-valvular
atrial fibrillation: a cohort study using primary care data in Germany. PloS one 2017;12:e0185642.

v
o

r
P

PUBMED | CROSSREF

l
a

61. Liu C, Du X, Jiang C, et al. Long-term persistence with newly-initiated warfarin or non-VKA oral
anticoagulant (NOAC) in patients with non-valvular atrial fibrillation: insights from the prospective
China-AF registry. Med Sci Monit 2019;25:2649-57.
PUBMED | CROSSREF

n
o

62. Willey V, Franchino-Elder J, Fu AC, et al. Treatment and persistence with oral anticoagulants among
newly diagnosed patients with non-valvular atrial fibrillation: a retrospective observational study in a US
commercially insured and Medicare advantage population. BMJ Open 2018;8:e020676.

i
is

PUBMED | CROSSREF

63. Deitelzweig SB, Buysman E, Pinsky B, et al. Warfarin use and stroke risk among patients with nonvalvular
atrial fibrillation in a large managed care population. Clin Ther 2013;35:1201-10.
PUBMED | CROSSREF

64. Wang ZZ, Du X, Wang W, et al. Long-term persistence of newly initiated warfarin therapy in Chinese
patients with nonvalvular atrial fibrillation. Circ Cardiovasc Qual Outcomes 2016;9:380-7.

v
o

PUBMED | CROSSREF

65. Han S, Jeong HS, Kim H, Suh HS. The treatment pattern and adherence to direct oral anticoagulants in
patients with atrial fibrillation aged over 65. PLoS One 2019;14:e0214666.

r
P

PUBMED | CROSSREF

66. Beyer-Westendorf J, Ehlken B, Evers T. Real-world persistence and adherence to oral anticoagulation for
stroke risk reduction in patients with atrial fibrillation. Europace 2016;18:1150-7.
PUBMED | CROSSREF

67. Hohnloser SH, Basic E, Nabauer M. Changes in oral anticoagulation therapy over one year in 51,000 atrial
fibrillation patients at risk for stroke: a practice-derived study. Thromb Haemost 2019;119:882-93.
PUBMED | CROSSREF

68. Björck F, Ek A, Johansson L, Själander A. Warfarin persistence among atrial fibrillation patients - why is
treatment ended? Cardiovasc Ther 2016;34:468-74.
PUBMED | CROSSREF

69. Simons LA, Ortiz M, Freedman SB, Waterhouse BJ, Colquhoun D, Thomas G. Improved persistence with
non-vitamin-K oral anticoagulants compared with warfarin in patients with atrial fibrillation: recent
Australian experience. Curr Med Res Opin 2016;32:1857-61.
PUBMED | CROSSREF

70. Shiga T, Naganuma M, Nagao T, et al. Persistence of non-vitamin K antagonist oral anticoagulant use in
Japanese patients with atrial fibrillation: a single-center observational study. J Arrhythm 2015;31:339-44.
PUBMED | CROSSREF

71. Zalesak M, Siu K, Francis K, et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation
patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes 2013;6:567-74.
PUBMED | CROSSREF

https://e-kcj.org

https://doi.org/10.4070/kcj.2019.0234

22/25

Anticoagulation Prescription and Persistence

72. Brown JD, Shewale AR, Talbert JC. Adherence to rivaroxaban, dabigatran, and apixaban for stroke
prevention for newly diagnosed and treatment-naive atrial fibrillation patients: an update using 2013–
2014 data. J Manag Care Spec Pharm 2017;23:958-67.
PUBMED | CROSSREF

73. Engdahl J, Holmén A, Rosenqvist M, Strömberg U. A prospective 5-year follow-up after population-based
systematic screening for atrial fibrillation. Europace 2018;20:f306-11.
PUBMED | CROSSREF

74. Fischer MA, Stedman MR, Lii J, et al. Primary medication non-adherence: analysis of 195,930 electronic
prescriptions. J Gen Intern Med 2010;25:284-90.
PUBMED | CROSSREF

75. Stephenson JJ, Shinde MU, Kwong WJ, Fu AC, Tan H, Weintraub WS. Comparison of claims vs patientreported adherence measures and associated outcomes among patients with nonvalvular atrial fibrillation
using oral anticoagulant therapy. Patient Prefer Adherence 2018;12:105-17.

l
a

PUBMED | CROSSREF

76. Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies
on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol
2012;52:275-301.

n
o

PUBMED | CROSSREF

77. Obamiro KO, Chalmers L, Lee K, Bereznicki BJ, Bereznicki LR. Adherence to oral anticoagulants in atrial
fibrillation: an Australian survey. J Cardiovasc Pharmacol Ther 2018;23:337-43.

i
is

PUBMED | CROSSREF

78. Gallagher AM, Rietbrock S, Plumb J, van Staa TP. Initiation and persistence of warfarin or aspirin in
patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke
prophylaxis? J Thromb Haemost 2008;6:1500-6.

v
o

r
P

l
a

PUBMED | CROSSREF

79. Fang MC, Go AS, Chang Y, et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ
Cardiovasc Qual Outcomes 2010;3:624-31.
PUBMED | CROSSREF

n
o

80. Gomes T, Mamdani MM, Holbrook AM, Paterson JM, Juurlink DN. Persistence with therapy among
patients treated with warfarin for atrial fibrillation. Arch Intern Med 2012;172:1687-9.
PUBMED | CROSSREF

i
is

81. Chatterjee S, Sardar P, Giri JS, Ghosh J, Mukherjee D. Treatment discontinuations with new oral agents
for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801
patients. Mayo Clin Proc 2014;89:896-907.
PUBMED | CROSSREF

82. Weeda ER, Coleman CI, McHorney CA, Crivera C, Schein JR, Sobieraj DM. Impact of once- or twicedaily dosing frequency on adherence to chronic cardiovascular disease medications: a meta-regression
analysis. Int J Cardiol 2016;216:104-9.

v
o

PUBMED | CROSSREF

83. Crowley MJ, Zullig LL, Shah BR, et al. Medication non-adherence after myocardial infarction: an
exploration of modifying factors. J Gen Intern Med 2015;30:83-90.

r
P

PUBMED | CROSSREF

84. Gerber BS, Cho YI, Arozullah AM, Lee SY. Racial differences in medication adherence: a cross-sectional
study of Medicare enrollees. Am J Geriatr Pharmacother 2010;8:136-45.
PUBMED | CROSSREF

85. McKenzie SJ, McLaughlin D, Clark J, Doi SA. The burden of non-adherence to cardiovascular medications
among the aging population in Australia: a meta-analysis. Drugs Aging 2015;32:217-25.
PUBMED | CROSSREF

86. Suzuki T, Shiga T, Omori H, Tatsumi F, Nishimura K, Hagiwara N. Self-reported non-adherence to
medication in Japanese patients with cardiovascular diseases. Am J Cardiovasc Drugs 2018;18:311-6.
PUBMED | CROSSREF

87. Miyazaki M, Nakashima A, Nakamura Y, et al. Association between medication adherence and illness
perceptions in atrial fibrillation patients treated with direct oral anticoagulants: an observational crosssectional pilot study. PLoS One 2018;13:e0204814.
PUBMED | CROSSREF

88. Smet L, Heggermont WA, Goossens E, et al. Adherence, knowledge, and perception about oral
anticoagulants in patients with atrial fibrillation at high risk for thromboembolic events after
radiofrequency ablation. J Adv Nurs 2018;74:2577-87.
PUBMED | CROSSREF

https://e-kcj.org

https://doi.org/10.4070/kcj.2019.0234

23/25

Anticoagulation Prescription and Persistence

89. Pandya EY, Bajorek B. Factors affecting patients' perception on, and adherence to, anticoagulant therapy:
anticipating the role of direct oral anticoagulants. Patient 2017;10:163-85.
PUBMED | CROSSREF

90. Fan JH, Lyons SA, Goodman MS, Blanchard MS, Kaphingst KA. Relationship between health literacy and
unintentional and intentional medication nonadherence in medically underserved patients with type 2
diabetes. Diabetes Educ 2016;42:199-208.
PUBMED | CROSSREF

91. Abdou JK, Auyeung V, Patel JP, Arya R. Adherence to long-term anticoagulation treatment, what is known
and what the future might hold. Br J Haematol 2016;174:30-42.
PUBMED | CROSSREF

92. Rolls CA, Obamiro KO, Chalmers L, Bereznicki LR. The relationship between knowledge, health literacy,
and adherence among patients taking oral anticoagulants for stroke thromboprophylaxis in atrial
fibrillation. Cardiovasc Ther 2017;35:e12304.

l
a

PUBMED | CROSSREF

93. Zhao S, Zhao H, Wang X, et al. Factors influencing medication knowledge and beliefs on warfarin
adherence among patients with atrial fibrillation in China. Patient Prefer Adherence 2017;11:213-20.

n
o

PUBMED | CROSSREF

94. Wei Y, Xu J, Wu H, et al. Survey of antithrombotic treatment in rural patients (>60 years) with atrial
fibrillation in East China. Sci Rep 2018;8:6830.

i
is

PUBMED | CROSSREF

95. Wilke T, Bauer S, Mueller S, Kohlmann T, Bauersachs R. Patient preferences for oral anticoagulation
therapy in atrial fibrillation: a systematic literature review. Patient 2017;10:17-37.
PUBMED | CROSSREF

96. Clarkesmith DE, Lip GY, Lane DA. Patients' experiences of atrial fibrillation and non-vitamin K
antagonist oral anticoagulants (NOACs), and their educational needs: a qualitative study. Thromb Res
2017;153:19-27.

v
o

r
P

l
a

PUBMED | CROSSREF

97. Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: a review from the
patient's perspective. Ther Clin Risk Manag 2008;4:269-86.

n
o

PUBMED | CROSSREF

98. Vinereanu D, Lopes RD, Bahit MC, et al. A multifaceted intervention to improve treatment with oral
anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial. Lancet
2017;390:1737-46.

i
is

PUBMED | CROSSREF

99. Montalescot G, Brotons C, Cosyns B, et al. Educational impact on apixaban adherence in atrial fibrillation
(the AEGEAN STUDY): a randomized clinical trial. Am J Cardiovasc Drugs. 2019 [Epub ahead of print].

v
o

PUBMED | CROSSREF

100. Desteghe L, Vijgen J, Koopman P, et al. Telemonitoring-based feedback improves adherence to
non-vitamin K antagonist oral anticoagulants intake in patients with atrial fibrillation. Eur Heart J
2018;39:1394-403.

r
P

PUBMED | CROSSREF

101. Di Minno A, Spadarella G, Tufano A, Prisco D, Di Minno G. Ensuring medication adherence with
direct oral anticoagulant drugs: lessons from adherence with vitamin K antagonists (VKAs). Thromb Res
2014;133:699-704.
PUBMED | CROSSREF

102. Dupclay L, Eaddy M, Jackson J, Raju A, Shim A. Real-world impact of reminder packaging on
antihypertensive treatment adherence and persistence. Patient Prefer Adherence 2012;6:499-507.
PUBMED

103. Aggarwal B, Liao M, Mosca L. Medication adherence is associated with having a caregiver among cardiac
patients. Ann Behav Med 2013;46:237-42.
PUBMED | CROSSREF

104. Hui DS, Morley JE, Mikolajczak PC, Lee R. Atrial fibrillation: a major risk factor for cognitive decline. Am
Heart J 2015;169:448-56.
PUBMED | CROSSREF

105. Stacey D, Légaré F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions.
Cochrane Database Syst Rev 2017;4:CD001431.
PUBMED

106. Thakkar J, Kurup R, Laba TL, et al. Mobile telephone text messaging for medication adherence in chronic
disease: a meta-analysis. JAMA Intern Med 2016;176:340-9.
PUBMED | CROSSREF

https://e-kcj.org

https://doi.org/10.4070/kcj.2019.0234

24/25

Anticoagulation Prescription and Persistence

107. Santo K, Singleton A, Rogers K, et al. Medication reminder applications to improve adherence in
coronary heart disease: a randomised clinical trial. Heart 2018;105:323-9.
PUBMED | CROSSREF

108. Ahmed I, Ahmad NS, Ali S, et al. Medication adherence apps: review and content analysis. JMIR mHealth
uHealth 2018;6:e62.
PUBMED | CROSSREF

109. Rohan JM, Drotar D, Alderfer M, et al. Electronic monitoring of medication adherence in early
maintenance phase treatment for pediatric leukemia and lymphoma: identifying patterns of
nonadherence. J Pediatr Psychol 2015;40:75-84.
PUBMED | CROSSREF

110. van Heuckelum M, van den Ende CH, Houterman AE, Heemskerk CP, van Dulmen S, van den Bemt
BJ. The effect of electronic monitoring feedback on medication adherence and clinical outcomes: a
systematic review. PLoS One 2017;12:e0185453.

l
a

PUBMED | CROSSREF

111. Aldeer M, Javanmard M, Martin R. A review of medication adherence monitoring technologies. Appl Syst
Innov 2018;1:14.

n
o

CROSSREF

i
is

v
o

r
P

r
P
https://e-kcj.org

n
o

i
is

v
o

https://doi.org/10.4070/kcj.2019.0234

l
a

25/25

